The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3747-3751

  Chauhan, Neeraj ^a   Kruppa, Michael ^a   Calderone, Richard ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; CASPOFUNGIN; CHECKPOINT KINASE 1; FLUCONAZOLE; FUNGAL PROTEIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; PROTEIN SSK1P; REGULATOR PROTEIN; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CULTURE MEDIA; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PHOSPHORYLATION; PROTEIN KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 34948866723     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00929-07     Document Type: Article

References (28)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Andes, D., and M. van Oqtrop. 1999. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. 43:2116-2120.
3. Aperis, G., N. Myriounis, E. Spanakis, and E. Mylonakis. 2006. Developments in the treatment of candidiasis: more choices and new challenges. Exp. Opin. Investig. Drugs 15:1319-1336.
4. Bader, O., M. Schaller, S. Klein, J. Kukula, K. Haack, F. Muhlschlegel, H. Korting, W. Schafer, and B. Hube. 2001. The KEX2 gene of Candida glabrata is required for cell surface integrity. Mol. Microbiol. 41:1431-1444.
5. Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanisms of increased resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777.
6. Calera, J. A., and R. Calderone. 1999. Identification of a putative response regulator, two-component phosphorelay gene (CaSSK1) from Candida albicans. Yeast 15:1243-1254.
7. Calera, J. A., and R. Calderone. 1999. Flocculation of hyphae is associated with a deletion in the putative CaHK1 two-component histidine kinase gene from Candida albicans. Microbiology 145:1431-1442.
8. Calera, J. A., X. J. Zhao, and R. Calderone. 2000. Defective hyphal development and avirulence caused by a deletion of the SSK1 response regulator gene in Candida albicans. Infect. Immun. 68:518-525.
9. Chauhan, N., J.-P. Latge, and R. Calderone. 2006. Signaling and oxidant adaptation in Candida albicans and Aspergillus fumigatus. Nat. Microbiol. Rev. 4:435-444.
10. Chauhan, N., D. Inglis, J. Pia, D. Li, J. A. Calera, and R. Calderone. 2003. The SSK1 of Candida albicans is associated with oxidative stress adaptation and cell wall biosynthesis. Eukaryot. Cell 2:1018-1024.
11. Cornet, M., C. Gaillardin, and M. Richard. 2006. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity. Antimicrob. Agents Chemother. 50:3492-3495.
12. Espinol-Ingroff, A., F. Barchie, M. Cuenca-Estrella, M. Pfaller, M. Rinaldi, J. Rodríguez-Tudela, and P. Verwey. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posiconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
13. Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
14. Jain, P., I. Akula, and T. Edlind. 2003. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 47:3195-3201.
15. Kaur, R., I. Castano, and B. Cormack. 2004. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob. Agents Chemother. 48: 1600-1613.
16. Krcmery, V., and A. Barnes. 2002. Non-albicans Candida spp. causing fungemia: pathogenicity and anti-fungal resistance. J. Hosp. Infect. 50:243-260.
17. Kruppa, M., and R. Calderone. 2006. Two-component signal transduction in human fungal pathogens. FEMS Yeast Res. 6:149-159.
18. Mascher, T., M. Heintz, D. Zahner, M. Merai, and R. Hakenbeck. 2006. The CiaRH system of Streptococcus pneumoniae prevents lysis during stress induced by treatment with cell wall inhibitors and by mutations in pbp2x involved in β-lactam resistance. J. Bacteriol. 188:1959-1968.
19. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davison, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Lavediere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Prioa, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
21. Paderu, P., S. Park, and D. S. Perlin. 2004. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob. Agents Chemother. 48:3845-3849.
22. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.
23. Pfaller, M. A., D. J. Diekema, R. N. Jones, S. A. Messe, R. J. Hollis, et al. 2002. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40:852-856.
24. Prasad, T., A. Chandra, C. K. Mukhopadhyay, and R. Prasad. 2006. Unexpected link between iron and drug resistance of Candida spp.: iron depletion enhances membrane fluidity and drug diffusion, leading to drug-susceptible cells. Antimicrob. Agents Chemother. 50:3597-3606.
25. Sabatelli, F., R. Patel, P. Mann, C. Mendrick, C. Norris, R. Hare, D. Loebenberg, T. Black, and P. McNicholas. 2006. In vitro activities of posaconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
26. Sharma, K., M. Gupta, M. Pathak, N. Gupta, A. Koul, S. Sarangi, R. Baweja, and Y. Singh. 2006. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. J. Bacteriol. 188:2936-2944.
27. Szurmant, H., and G. W. Gordal. 2004. Diversity of Chemotaxis mechanisms among bacteria and Archaea. Annu. Rev. Mol. Biol. Rev. 68:301-319.
28. Tsai, H.-F., M. Bard, K. Izumikawa, A. Krol, A. Sturm, N. Culbertson, C. Pierson, and J. Bennett. 2004. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob. Agents Chemother. 48:2483-2489.